article thumbnail

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharmacy Times

December 21, 2004. PR Newswire. June 10, 2025. Accessed June 10, 2025. Meloxicam: Selective COX-2 inhibition in clinical practice. Seminars in Arthritis and Rheumatism.

article thumbnail

ICH Q6(R1): test criteria and specifications

European Pharmaceutical Review

EMA/CHMP/ICH/167068/2004. Internet] Vaccines Europe. The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA. Pharmaceutics. 2021; 13(1): 48. ICH Q8(R2) Pharmaceutical Development – Scientific Guideline. 22 June 2017. ICH Q9(R1) Quality Risk Management – Scientific Guideline. 3 February 2023.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

207 community hospital presidents and CEOs to know | 2025

Beckers Hospital Review

Gleason joined NMC Health in 2004. Hoey directed field hospital operations and oversaw a mass vaccination program that administered over 140,000 doses. He also serves on the board of trustees for the New Jersey Hospital Association. Vallerie Gleason. President and CEO of NMC Health (Newton, Kan.). As CEO, Ms. During the pandemic, Ms.

Hospitals 125
article thumbnail

Panel urges FDA to remove warnings on hormonal menopause therapy

BioPharma Dive

An arm of the trial arm involving use of estrogen only was also stopped early in 2004 due to an apparent increased risk of stroke. The study was stopped early in 2002 after researchers observed an increased risk of breast cancer and heart disease. Makary has previously been critical of the warnings on MHT and advocated for its greater use.

article thumbnail

Bavarian Nordic secures $156.8m US vaccine deal

Pharmaceutical Business Review

Additionally, the contract includes around $17m for additional services from 2025 to 2027, which encompasses the storage of vaccine doses within the US. The vaccine, known as MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic, is marketed under various brand names, JYNNEOS, IMVANEX, and IMVAMUNE.

article thumbnail

Reconfiguring COVID and influenza vaccines for long-term effectiveness

pharmaphorum

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology. Antibodies cover the pathogen of the virus and neutralise it.

article thumbnail

Pharmaceutical industry: 2023 in retrospect

European Pharmaceutical Review

During 2023, there were five revisions to the European Medicines Agency ’s (EMA’s) Questions and Answers (Q&As) for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products. 2004; 29: 100298. J Pharm Sci.